Carl Zeiss Meditec last week announced that it is a new shareholder of MicroOptx.
Minneapolis-based MicroOptx develops minimally invasive glaucoma surgery devices. The technology is designed to provide effective reduction of intraocular pressure with one surgical procedure.
Zeiss’s investment will support the surgical treatments for glaucoma and complement its equipment and consumables in ophthalmic surgery.
“The investment in MicroOptx will give Zeiss an early position in this new technology designed to increase MIGS adoption for treating glaucoma,” James Mazzo, president of ophthalmic devices at Zeiss, said in a press release.